NO923643L - Legemiddel for behandling av gastrointestinale forstyrrelser - Google Patents

Legemiddel for behandling av gastrointestinale forstyrrelser

Info

Publication number
NO923643L
NO923643L NO92923643A NO923643A NO923643L NO 923643 L NO923643 L NO 923643L NO 92923643 A NO92923643 A NO 92923643A NO 923643 A NO923643 A NO 923643A NO 923643 L NO923643 L NO 923643L
Authority
NO
Norway
Prior art keywords
gastrointestinal disorders
drugs
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO92923643A
Other languages
English (en)
Other versions
NO301456B1 (no
NO923643D0 (no
Inventor
Andrew Alexander Mccolm
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO923643D0 publication Critical patent/NO923643D0/no
Publication of NO923643L publication Critical patent/NO923643L/no
Publication of NO301456B1 publication Critical patent/NO301456B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO923643A 1991-09-20 1992-09-18 Farmasöytisk preparat for behandling eller forebyggelse av gastrointestinale forstyrrelser NO301456B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919120131A GB9120131D0 (en) 1991-09-20 1991-09-20 Medicaments

Publications (3)

Publication Number Publication Date
NO923643D0 NO923643D0 (no) 1992-09-18
NO923643L true NO923643L (no) 1993-03-22
NO301456B1 NO301456B1 (no) 1997-11-03

Family

ID=10701750

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923643A NO301456B1 (no) 1991-09-20 1992-09-18 Farmasöytisk preparat for behandling eller forebyggelse av gastrointestinale forstyrrelser

Country Status (26)

Country Link
US (3) US5674858A (no)
EP (1) EP0533281B1 (no)
JP (1) JPH0692850A (no)
KR (1) KR100257367B1 (no)
AT (2) ATE228835T1 (no)
BE (1) BE1005808A5 (no)
CA (1) CA2078579A1 (no)
CH (1) CH685372A5 (no)
CY (1) CY2012A (no)
CZ (1) CZ282840B6 (no)
DE (1) DE69232864T2 (no)
ES (1) ES2188582T3 (no)
FR (1) FR2682040B1 (no)
GB (2) GB9120131D0 (no)
HK (1) HK78197A (no)
HU (1) HU211170A9 (no)
IE (1) IE922673A1 (no)
IL (1) IL103213A (no)
IT (1) IT1262993B (no)
MX (1) MX9205313A (no)
NO (1) NO301456B1 (no)
NZ (1) NZ244390A (no)
PT (1) PT533281E (no)
RU (1) RU2116071C1 (no)
SK (1) SK280283B6 (no)
ZA (1) ZA927157B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005315A1 (fr) * 1988-10-31 1990-05-17 Sumitomo Cement Co., Ltd. Articles antireflet, procede de production et preparation servant de revetement
WO1994028898A1 (en) * 1993-06-15 1994-12-22 Pfizer Inc. H2-antagonists as immune stimulants in bacterial infections of cattle or swine
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
JPH10512877A (ja) * 1995-01-26 1998-12-08 ニコムド イメージング エイ／エス ビスマス化合物
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US5900410A (en) * 1996-08-27 1999-05-04 Hartmann; John F. Monotherapy of peptic ulcers and gastritis
DE19709897A1 (de) * 1997-03-11 1998-09-17 Hoechst Ag Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
US6017950A (en) 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
IT1296980B1 (it) * 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
WO2000066174A2 (en) * 1999-04-29 2000-11-09 Russinsky Limited Compounds
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
RU2207115C1 (ru) * 2001-12-27 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Противомикробное средство тариферид
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
BRPI0408442A (pt) 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
CA2886042C (en) 2012-09-28 2015-11-24 Santen Pharmaceutical Co., Ltd. Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
US11890295B2 (en) 2018-08-31 2024-02-06 Korea Institute Of Geoscience And Mineral Resources Helicobacter pylori eradication method including step for orally administering composition including complex of non-absorbable antibiotic and clay mineral to subject

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB772567A (en) * 1954-05-06 1957-04-17 Siegfried Fischl Preparation of stable, injectable bismuth-containing pharmaceutical compositions and the compositions formed thereby
WO1986005981A1 (en) * 1985-04-18 1986-10-23 Borody Thomas J Treatment of non-ulcer dyspepsia with bismuth salts
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3650504T2 (de) * 1985-06-13 1996-10-31 Marshall Barry James Verfahren und Zusammensetzungen zur Behandlung von gastrointestinalen Störungen
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
CH679582A5 (no) * 1988-07-18 1992-03-13 Glaxo Group Ltd
FI910088A7 (fi) * 1990-01-09 1991-07-10 Brocades Pharma Bv Oraalinen farmaseuttinen koostumus
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
WO1992010302A1 (de) * 1990-12-04 1992-06-25 Mueller Werner Bewässerungsanlage für hallenböden von reithallen, treibhäusern u. dgl.
US5176698A (en) * 1991-01-09 1993-01-05 Scimed Life Systems, Inc. Vented dilatation cathether and method for venting
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
AU3086995A (en) * 1994-08-18 1996-03-14 Hiroyuki Minakami Wheel fixing device, pallet/truck and wheel fixing method, automatic wheel fixing device and mode interchange

Also Published As

Publication number Publication date
HU211170A9 (en) 1995-11-28
CY2012A (en) 1998-02-20
FR2682040B1 (fr) 1994-10-28
IT1262993B (it) 1996-07-23
FR2682040A1 (fr) 1993-04-09
GB2259647A (en) 1993-03-24
EP0533281A1 (en) 1993-03-24
NO301456B1 (no) 1997-11-03
ITRM920681A1 (it) 1994-03-18
EP0533281B1 (en) 2002-12-04
ITRM920681A0 (it) 1992-09-18
GB9219749D0 (en) 1992-10-28
IL103213A0 (en) 1993-02-21
PT533281E (pt) 2003-04-30
KR100257367B1 (ko) 2000-05-15
US5674858A (en) 1997-10-07
ES2188582T3 (es) 2003-07-01
HK78197A (en) 1997-06-20
DE69232864T2 (de) 2003-11-20
US5668130A (en) 1997-09-16
ZA927157B (en) 1993-06-15
GB2259647B (en) 1995-11-29
US5629297A (en) 1997-05-13
IL103213A (en) 2000-02-29
ATE228835T1 (de) 2002-12-15
CZ287892A3 (en) 1993-12-15
AU663520B2 (en) 1995-10-12
AU2458492A (en) 1993-03-25
CZ282840B6 (cs) 1997-10-15
ATA186692A (de) 1997-09-15
MX9205313A (es) 1993-04-01
CA2078579A1 (en) 1993-03-21
DE69232864D1 (de) 2003-01-16
AT403656B (de) 1998-04-27
KR930005619A (ko) 1993-04-20
BE1005808A5 (fr) 1994-02-01
NO923643D0 (no) 1992-09-18
RU2116071C1 (ru) 1998-07-27
GB9120131D0 (en) 1991-11-06
SK280283B6 (sk) 1999-11-08
NZ244390A (en) 1997-06-24
SK287892A3 (en) 1995-06-07
JPH0692850A (ja) 1994-04-05
CH685372A5 (fr) 1995-06-30
IE922673A1 (en) 1993-03-24

Similar Documents

Publication Publication Date Title
NO923643D0 (no) Legemiddel for behandling av gastrointestinale forstyrrelser
NO903542D0 (no) Frysetoerket blanding og fremgangsmaate for oral administrering av legemidler, naeringsmidler og biologisk aktive materialer.
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
MY108146A (en) Medicaments for treating inflammatory conditions or for analgesia
DK481388D0 (da) Calciumtilskud
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
NO893142L (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
ATE199497T1 (de) Moenomycin als arzneimittel zur behandlung von magengeschwüren
IL67940A0 (en) 2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
DK598288D0 (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
NO167664C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive castanosperminestere og glycosider.
IT1240683B (it) Composizione farmaceutica contenente egf
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
IL85388A (en) Pharmaceutical compositions containing oxoquinazoline derivatives for the treatment of hyperuricaemia
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
NO922635D0 (no) Ny anvendelse av benzimidazolin-2-okso-1-karboksylsyrederivater
DE3871159D1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.
RU92004541A (ru) Лекарственные средства для лечения воспалительных состояний или для аналгезии
ATE59776T1 (de) Pharmazeutische zusammensetzung und behandlung.
ITMI913248A1 (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione e procedimento per la preparazione dei suddetti principi attivi
NO903504L (no) Doseringsbeholder for opptak og levering av midler for behandling av toey.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MARCH 2003